Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. develops precision oncology diagnostics and data products centered on blood and tissue testing for cancer care. Company news commonly covers the Guardant360 liquid biopsy and Guardant360 Tissue franchises, Guardant Reveal for molecular residual disease monitoring, Shield colorectal cancer screening, and InfinityAI real-world data and analytics.
Recurring updates include financial results across Oncology, Screening, and Biopharma & Data revenue categories; FDA companion diagnostic approvals for Guardant360 CDx; research presentations in tumor typing, therapy selection, methylation and multiomic testing; and biopharma collaborations that use Guardant tissue and liquid biopsy assays to support targeted therapy development.
Guardant Health (Nasdaq: GH) responded to a lawsuit from Illumina challenging its ownership of intellectual property related to blood tests. Guardant claims the lawsuit is an attempt to suppress competition, following its concerns about the antitrust implications of Illumina's acquisition of Grail. Despite legal challenges, Guardant remains committed to its mission of developing cancer screening tests. The company maintains that their long-term supply agreement with Illumina is intact and that they will vigorously defend their intellectual property rights.
Guardant Health, Inc. (Nasdaq: GH) has received regulatory approval from the Japanese Ministry of Health, Labour and Welfare for its Guardant360® CDx test, which profiles tumor mutations in patients with advanced solid tumors. The test will identify patients with microsatellite instability-high (MSI-High) tumors eligible for Keytruda® and Opdivo®. This approval enhances the company's commitment to improving cancer care through innovative blood-based diagnostics, following a prior approval for NSCLC in December 2021.
Guardant Health (Nasdaq: GH) announced it will present new findings from its next-generation Guardant SHIELD assay at the AACR Annual Meeting from April 8-13, 2022. The data highlights the assay's ability to detect early-stage cancers and accurately identify their tissue of origin. Co-CEO AmirAli Talasaz emphasized the company's commitment to enhancing cancer care. The presentation will cover various studies, including a highly-sensitive cell-free DNA assay and real-world effectiveness of CDK4/6 inhibitors for breast cancer.
Guardant Health, Inc. (NASDAQ: GH) announced that Palmetto GBA has granted coverage for its Guardant360 TissueNext™ test under the existing local coverage determination for next-generation sequencing of solid tumors. This tissue-based test aims to assist oncologists in identifying advanced cancer patients who may benefit from biomarker-informed treatments. Medicare will cover the test for fee-for-service patients with advanced solid tumor cancers. This marks an expansion of coverage for Guardant's tests and enhances access to genomic profiling for patients with advanced cancer.
Guardant Health reported strong Q4 2021 results with revenue of $108 million, a 38% increase year-over-year. For the full year, revenue reached $374 million, up 30%. Clinical tests surged by 48% to 25,600, while biopharma tests rose 36% to 6,600. Gross profit improved to $74.7 million with a 69% gross margin. Despite increased operating expenses of $172.9 million, the net loss narrowed to $90.9 million. The company expects 2022 revenue between $460 million and $470 million.
Guardant Health, a leading precision oncology company, will participate virtually in several key investor conferences in February and March 2022. The conferences include:
- 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 9:00 a.m. PT.
- Citi 2022 Healthcare Conference on February 24 at 11:45 a.m. PT.
- Cowen 42nd Annual Health Care Conference on March 8 at 10:30 a.m. PT.
Live and archived webcasts will be available on the company's website. Guardant Health aims to enhance cancer care through its innovative tests and analytics.
Guardant Health, Inc. (NASDAQ: GH) announced it will release its financial results for Q4 and the full year 2021 on February 23, 2022, after market close. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET). The event can be streamed live from the company’s website, with an archive available post-event. Guardant Health specializes in precision oncology, offering advanced diagnostic tests like Guardant360 and Guardant Reveal to enhance cancer care.
Guardant Health (Nasdaq: GH) announced positive data from the interim analysis of the COSMOS-CRC-01 study, showcasing the Guardant Reveal™ liquid biopsy test's efficacy in detecting molecular residual disease in early-stage colorectal cancer. The test can identify disease recurrence with a lead time of over six months post-surgery. Additionally, the Guardant360® test demonstrated comparable detection rates for microsatellite instability-high status in advanced gastrointestinal cancers. These findings will be presented at the 2022 ASCO Gastrointestinal Cancers Symposium from January 20-22, 2022.
Guardant Health has initiated the SHIELD LUNG study, enrolling nearly 10,000 patients over 36 months to evaluate its blood test for detecting lung cancer in high-risk individuals aged 50-80. The study will take place across 100 centers in the U.S. and Europe. Lung cancer remains a leading cause of cancer-related deaths, with only 14% of eligible individuals adhering to current screening guidelines. Successful study outcomes could support a PMA submission to the FDA.
Guardant Health (GH) announced a settlement with Foundation Medicine regarding digital sequencing technology patents. Foundation Medicine will pay Guardant Health $25 million and future royalties. This agreement results in the dismissal of all pending patent litigation between the two companies. Guardant Health's Co-CEO, Helmy Eltoukhy, emphasized the significance of this settlement, highlighting the recognition of their scientific discoveries and strong intellectual property rights.